COGT Bezuclastinib GIST PDUFA Nov 30: First Active-Drug Win

The FDA accepted Cogent Biosciences’ (COGT) New Drug Application for bezuclastinib (CGT9486) in combination with sunitinib for patients with gastrointestinal stromal tumors (GIST) who have received prior treatment with imatinib. The agency granted Priority Review with a PDUFA date of November 30, 2026. No advisory committee meeting is planned.

Cogent closed at $40.44 with a market cap of $6.91 billion. The stock has two PDUFA catalysts within 30 days: the GIST NDA on November 30 and a separate NDA for bezuclastinib in non-advanced systemic mastocytosis on December 30.

The PEAK trial data

The NDA is based on the Phase 3 PEAK trial, the first treatment ever to demonstrate a statistically significant advantage against an active comparator in GIST. Median progression-free survival was 16.5 months for bezuclastinib plus sunitinib versus 9.2 months for sunitinib alone (HR=0.50, 95% CI 0.39-0.65, p<0.0001). The objective response rate was 46% versus 26%. The combination was well tolerated, with no unique risks beyond the known safety profile of sunitinib.

The FDA granted Breakthrough Therapy Designation and Real-Time Oncology Review for the GIST indication, both of which streamline the review process. The full PEAK data were presented at ASCO on May 30, 2026.

Why GIST has been stuck for 20 years

GIST is a rare sarcoma of the digestive tract driven by mutations in the KIT or PDGFRA genes. Imatinib (Gleevec) has been the first-line standard since 2002, and sunitinib (Sutent) has been the second-line standard since 2006. No new second-line therapy has been approved in the two decades since. The treatment field has been stagnant because GIST tumors develop secondary KIT mutations that resist both drugs, and no therapy has successfully addressed that resistance mechanism.

Bezuclastinib is a selective KIT inhibitor designed to target both primary and secondary KIT mutations. In the PEAK trial, the combination of bezuclastinib plus sunitinib showed PFS benefit regardless of primary or secondary KIT mutation genotype, which is the mechanistic rationale for why the combination outperformed sunitinib alone.

The double-catalyst setup

Cogent has two PDUFA dates in a 30-day window, a rare setup that means the market must price in two separate approval decisions. The systemic mastocytosis NDA (December 30) is based on the SUMMIT trial, which showed an 8.91-point placebo-adjusted improvement in Total Symptom Score at 24 weeks (p=0.0002) and an 87.4% tryptase response versus 0% placebo. We covered that indication in our rare disease PDUFA catalysts analysis.

For investors, the question is whether the $6.91 billion valuation is pricing in one approval or two. If both are approved, Cogent would have a franchise spanning oncology (GIST) and rare disease (systemic mastocytosis) with the same molecule.

What to watch

The main risk is that the PEAK trial was open-label, which can introduce bias in PFS assessment. The FDA did not request an advisory committee, which signals confidence in the data, but the agency could still raise concerns about the open-label design or the choice of sunitinib monotherapy as the comparator. The secondary KIT mutation profile and whether the FDA specifies a companion diagnostic for mutation testing will also matter for the label. Cogent also initiated a new trial of bezuclastinib combination in first-line GIST patients, which extends the franchise potential but is years from readout.

What It Means for the Trade

The double-PDUFA structure — November 30 for GIST, December 30 for systemic mastocytosis — is the rarest kind of catalyst calendar: two decisions on the same molecule, thirty days apart, in two entirely different markets. The $6.91 billion valuation is therefore not pricing “a biotech with a filing” but a franchise question: one approval makes bezuclastinib a niche oncology drug with rare-disease optionality; two approvals make it one molecule spanning oncology and immunology with separately-sequenced growth curves. The PEAK data is the stronger regulatory package — a randomized Phase 3 against an active comparator with a clean hazard ratio (0.50, 16.5 versus 9.2 months median PFS) and Priority Review plus Real-Time Oncology Review — while SUMMIT’s mastocytosis package (8.91-point TSS improvement, 87.4% tryptase response) targets an indication where competition is thinner and pricing power higher. The market’s job between now and year-end is to figure out whether both are in the price; the honest answer is that two-approval scenarios rarely trade fully priced before the first decision.

The GIST win itself deserves its historical weight. No therapy has beaten an active comparator in this disease in twenty years — the sequence of approvals since imatinib has been incremental, mostly against placebo or best supportive care, because secondary KIT mutations create such heterogeneous resistance that single agents can’t cover the escape landscape. Bezuclastinib’s design — broad coverage of primary and secondary KIT mutation genotypes — is why the combination beat sunitinib alone on PFS across mutation subtypes, and the open-label concern is real but bounded: PFS in GIST is measured by RECIST imaging with defined assessment intervals, which limits (without eliminating) the bias channel.

Mechanism and Market Context

The biology of the two indications is the same target, two diseases. In GIST, KIT activation mutations drive the tumor and secondary mutations in the kinase domains create the resistance that imatinib and sunitinib can’t suppress — a selective KIT inhibitor engineered against the full mutation spectrum attacks the disease’s actual escape mechanism. In systemic mastocytosis, KIT D816V drives pathologic mast cell accumulation — the same target, an entirely different disease biology, and bezuclastinib’s tryptase response rate in SUMMIT is the direct pharmacodynamic evidence of KIT-driven disease control. This one-molecule-two-franchises structure is what makes the risk math interesting: a GIST approval alone supports an oncology revenue stream in a market of a few thousand patients per line of therapy; the mastocytosis approval adds a chronic rare-disease market with symptom-burden-based endpoints, recurring therapy, and a payer landscape familiar with orphan pricing.

The first-line GIST combination trial already initiated is the quiet franchise-extension lever: imatinib’s first-line position is the largest segment of the market, and any combination that shows benefit there rewrites peak-sales math far beyond the second-line entry point.

Risks and What Could Go Wrong

1. The FDA raises the open-label issue at review or requires confirmation on the primary analysis — a CRL or delay on the first of the two PDUFAs resets the whole double-catalyst structure and the valuation premium.
2. The mastocytosis review draws label-restricting language (advanced-only, or TSS-claim limitations) that caps the rare-disease economics below the SUMMIT topline’s implied model.
3. Companion-diagnostic requirements on the GIST label: mutation-genotype gating could narrow the addressable population to tested subsets, slowing launch adoption.
4. Two binary events in thirty days means the volatility is structural — a first approval does not de-risk the second, and the market will re-run the odds after November 30 regardless.

Position read: COGT is a two-binary compounder setup with strong data on both legs — the disciplined trade sizes the pair as correlated-but-distinct events rather than doubling up on one thesis. November 30 is the first gate; everything re-prices off it.